Eyepoint Pharmaceuticals (EYPT) Institutional Ownership

99.41% of Eyepoint Pharmaceuticals' stock is owned by institutional investors. Learn more on EYPT's institutional investor holdings.

Of the 143 institutional investors that purchased Eyepoint Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Federated Hermes Inc. ($4.28M), Paradigm Biocapital Advisors LP ($3.69M), Janus Henderson Group PLC ($3.60M), Suvretta Capital Management LLC ($3.24M), RA Capital Management L.P. ($3.18M), Adage Capital Partners GP L.L.C. ($3.01M), and Commodore Capital LP ($2.83M).

Institutional investors have bought a total of 32,301,254 shares in the last 24 months. This purchase volume represents approximately $503.46M in transactions.

Of the 49 institutional investors that sold Eyepoint Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Orbimed Advisors LLC ($1.40M), Adage Capital Partners GP L.L.C. ($859.78K), Patient Square Capital LP ($701.98K), Suvretta Capital Management LLC ($611.38K), JPMorgan Chase & Co. ($582.23K), Woodline Partners LP ($400.07K), and Goldman Sachs Group Inc. ($264.85K).

Institutional investors have sold a total of 7,480,493 shares in the last 24 months. This volume of shares sold represents approximately $111.50M in transactions.